About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi as its Chief Executive Officer (CEO), effective immediately. "We are delighted to welcome Ivor Elrifi as the new CEO of Tiziana Life Sciences," said Gabriele Cerrone, Fo ...

"We are thrilled to receive Fast Track designation from the FDA for intranasal foralumab for the treatment of Multiple Sclerosis," said Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences. "This designation underscores the potential of foralumab to address critical unmet needs in the treatment of neurodegenerative diseases. We are committed to advancing this promising therapy as quickly as possible to benefit patients." Foralumab, a fully human anti-CD3 monoclonal antibody, is a biol ...

About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The Canberra Times, an ...

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes today announced that it had received non-dilutive funding of $3.4 million and issued a corporate update video available here. About Foralumab About Tiziana Life Sciences For further inquiries: [1] https://www.pnas.org/doi/10.1073/pnas.2220272120 Gabriele Cerro ...

文章核心观点 - 公司获340万美元非稀释资金支持鼻内福拉珠单抗2期试验及阿尔茨海默病研究，并发布公司更新视频 [1][4] 公司情况 - 公司是临床阶段生物制药公司，用变革性药物递送技术开发突破性疗法，创新鼻腔给药法相比静脉给药在疗效、安全性和耐受性上有提升潜力 [4] - 公司领先候选药物鼻内福拉珠单抗是唯一全人抗CD3单克隆抗体，在既往研究中展现出良好安全性和临床反应，其免疫疗法替代途径技术已获专利且有多项申请待批，有望实现广泛管线应用 [4] 资金用途 - 340万美元非稀释资金用于支持鼻内福拉珠单抗在非活动性继发进展型多发性硬化症的2期试验及阿尔茨海默病研究，公司还将在短期内探索获取更多非稀释资金的途径 [4] 药物情况 - 福拉珠单抗能结合T细胞受体，通过调节T细胞功能抑制炎症，在COVID、多发性硬化症患者及健康受试者中均有此效果 [4] - 非活动性继发进展型多发性硬化症鼻内福拉珠单抗2期试验于2023年11月开始筛选患者，鼻用抗CD3单克隆抗体免疫调节是治疗神经炎症和神经退行性人类疾病的新途径 [4]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

文章核心观点 - 蒂齐亚娜生命科学公司宣布美国食品药品监督管理局（FDA）允许鼻内福拉珠单抗在一名中度阿尔茨海默病患者中通过扩大使用（EA）研究性新药（IND）申请使用，公司认为福拉珠单抗可能是治疗阿尔茨海默病的潜在突破性疗法 [1][3] 关于福拉珠单抗 - 福拉珠单抗是唯一的全人抗CD3单克隆抗体（mAb），可结合T细胞受体，通过调节T细胞功能来抑制炎症，从而抑制多种免疫细胞亚群的效应特征，该效果已在COVID患者、多发性硬化症患者以及健康正常受试者中得到证实 [8] - 鼻内抗CD3单克隆抗体的免疫调节代表了治疗神经炎症和神经退行性人类疾病的新途径 [8] 关于蒂齐亚娜生命科学公司 - 蒂齐亚娜生命科学公司是一家临床阶段的生物制药公司，利用变革性药物递送技术开发突破性疗法，以实现免疫疗法的替代途径 [8] - 公司领先候选药物鼻内福拉珠单抗已在多项研究中显示出良好的安全性和临床反应，其免疫疗法替代途径技术已获得专利，还有多项申请正在进行中，有望实现广泛的产品线应用 [8] 公司动态 - 公司此前宣布了2a期早期症状性阿尔茨海默病研究的IND许可，此次FDA额外许可使公司能在不符合批准疗法条件的中度阿尔茨海默病患者中研究鼻内福拉珠单抗 [3] - 非活动性继发性进行性多发性硬化症（SPMS）鼻内福拉珠单抗2期试验（NCT06292923）于2023年11月开始筛选患者 [8] - 首席研究员霍华德·L·韦纳博士表示最早7月用鼻内福拉珠单抗治疗首位中度阿尔茨海默病患者，公司希望其能帮助减缓该患者认知衰退的进展，同时将与FDA密切合作评估治疗反应，并启动早期症状性阿尔茨海默病患者的2期研究 [7]

NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has allowed intranasal foralumab to be used under an Expanded Access (EA) IND in its first patient with moderate Alzheimer's disease. Expanded access IND's provide a pathway for patients to gain access to investigational ...